Recently, Hefei Leecan Pharmaceutical achieved a significant milestone. The capsule production line in E101 workshop and the new product HLDP0613 successfully passed the on-site verification of drug registration and GMP compliance inspection jointly conducted by the CDE Yangtze River Delta Sub-center and the Anhui Provincial Evaluation and Inspection Center. The verification, which was carried out from August 4th to 7th, 2026, focused on a comprehensive review and verification of the entire production chain, production process, and quality assurance system of slow-release and controlled-release solid dosage forms. The relevant production lines and the declared new product successfully passed this verification with high quality.
.png "/uploads/image/2026/09/20/图片2(1).png")
Previously, the company successfully completed the inspection of the ampoule production line (inhalation liquid formulation, final sterilization of small volume injection) in D102 workshop and the inspection of the new product HLDP0112/0506 two-in-one in September 2025. Both inspections were successfully passed, fully demonstrating the company's solid quality control capabilities and normalized compliance operation level. This is an authoritative recognition from the regulatory authorities of the comprehensive strength of Leecan Pharmaceutical in research and development, production, and quality management.
As a pharmaceutical enterprise deeply engaged in the research, development, and industrialization of high-end complex and innovative preparations, Hefei Leecan Pharmaceutical has always adhered to the strict quality bottom line, integrating compliance management throughout the entire product research, development, and production cycle. Taking this as a new starting point, the company will continue to optimize and iterate its quality management system, create higher-quality products with higher standards, and strive to build an industry benchmark enterprise, thereby contributing to the higher-quality development of the regional pharmaceutical and healthcare industry.
025-58181716
Share:
